Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy - Clinical progress

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 2, 2002, Pages 214-224

  Renhowe, Paul A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiogenesis; ATP competitive inhibitor; c kit; Cancer; EGFR; ErbB 2; FGFR; Growth factor receptor kinase; PDGFR; Raf; VEGFR

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ADENOSINE TRIPHOSPHATE; ADL 681; ANTINEOPLASTIC AGENT; CANERTINIB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IMATINIB; LAPATINIB; PACLITAXEL; PELITINIB; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RALTITREXED; SEMAXANIB; STEM CELL FACTOR RECEPTOR; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VATALANIB;

ANEMIA; ANOREXIA; AUTOCRINE EFFECT; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN CELL; MOUSE; NAUSEA; NONHUMAN; RASH; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0036489885     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Growth factor receptor kinase inhibitors: Recent progress and clinical impact
2. Growth factor receptor kinases in cancer
3. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases
4. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
5. EGFR tyrosine kinase inhibitors in the treatment of cancer
6. Tyrosine kinase inhibitors-ZD1839 (Iressa)
7. ZD-1839 (AstraZeneca)
8. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
9. ZD1839, an epidermal growth factor tyosine kinase inhibitor selected for clinical development
10. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
11. The epidermal growth factor receptor and its inhibition in cancer therapy
12. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
13. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
14. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors
15. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
16. Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase
17. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
18. Phase I. Pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
19. OSI-774 (OSI Pharmaceuticals)
20. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
21. CI-1033: An irreversible inhibitor of the erbB family of oncogenes
22. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor
23. A phase I clinical and biomarker study of the novel pan-erbB tyrosine kinase inhibitor, CI-1033, in patients with solid tumors
24. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido-[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor
25. EKB-569: A new irreversible inhibitor of epidermal growth factor receptor tyrosine kinase for the treatment of cancer
26. Combinatorial chemoprevention of intestinal neoplasia
27. The use of irreversible inhibitors of EGF-R tyrosine kinase for the treatment of: Tumors, polycystic kidney disease and colonic polyps
28. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity
29. Tyrosine kinase inhibitors: From rational design to clinical trials
30. Optimization for the blockade of epidermal growth factor signaling for therapy of human pancreatic carcinoma
31. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers
32. A phase I and pharmacological study of intermittent dosing of PKI166, a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally to patients with advanced cancer
33. The discovery of a new anti-cancer agent GW2016: A potent, dual EGFR/ErbB-2 tyrosine kinase inhibitor
34. Antitumor activity of GW2016 in the EGFR positive human head and neck cancer xenograft, HN5
35. The characterization of novel, dual ErbB-2/EGFR, tyrosine Idnase inhibitors: Potential therapy for cancer
36. Antiangiogenic agents
37. Mechanisms of angiogenesis
38. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues
39. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer
40. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
41. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
42. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration
43. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
44. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
45. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas
46. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
47. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy
48. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
49. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
50. Treatment of patients with refractory, C-KIT positive, acute myeloid leukemia with SU5416, a novel receptor tyrosine kinase inhibitor
51. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
52. Indolinone tyrosine kinase inhibitors block kit activation and growth of small cell lung cancer cells
53. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
54. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
55. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases
56. ZD6474: Design, synthesis and structure activity relationship of a novel, orally active VEGF receptor tyrosine kinase inhibitor
57. Pharmacological efficacy of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in rat
58. Chronic and accute effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, on established human tumor xenografts
59. A phase I study of ZD6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumors
60. Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors: Results from a phase I study
61. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
62. SU-6668 SUGEN
63. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
64. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
65. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors
66. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenyl-aminopyrimidine class
67. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
68. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study
69. The role of oncogenic kinases in human cancer (Review)
70. Discovery of a novel raf kinase inhibitor
71. Potent raf kinase inhibitors from the diphenylurea class: Structure activity relationships
72. A novel raf-1 kinase inhibitor (RKI), blocks the RAF/MEK/ERK pathway in tumor cells
73. Anti-tumor efficacy of the orally active raf kinase inhibitor BAY 43-9006 in human tumor xenograft models